The CA 19-9 assay was first described by Del Villano et al. (1983) . It was soon shown that CA 19-9 is superior to CEA in the diagnosis of pancreatic cancer (Jalanklo et al., 1984; Haglund et al., 1986; Steinberg et al., 1986) , and since then CA 19-9 has been considered the standard marker for pancreatic cancer, with which other markers are compared. is defined by monoclonal antibody 1116 NS 19-9 (19-9 antibody), reacting with sialosyl-fucosyl-lactotetraose, i.e. sialylated Lewisa blood group antigen (Koprowski et al., 1979; Magnani et al., 1982) . CA 50, defined by monoclonal antibody C 50 (C 50 antibody) (Lindholm et al., 1983) , also reacts with sialylated Lewis, and in addition with at least one other carbohydrate, sialosyl-lactotetraose (Minsson et al., 1985; , although its affinity for this carbohydrate is much weaker (Minsson et al., 1985; . In spite of the broader reactivity of the C 50 antibody, the CA 19-9 assay shows a similar (Harmenberg et al., 1988) or even somewhat higher sensitivity for pancreatic cancer than the CA 50 test (Haglund et al., 1987; Benini et al., 1988) .
CA 242 is a new tumour marker, based on monoclonal antibody C 242 (C 242 antibody), obtained after immunisation of mice with a human colorectal adenocarcinoma cell line, COLO 205, the same carcinoma cell line against which the C 50 antibody was raised . The structure of the antigenic determinant is not completely defined, but it seems to be a sialylated carbohydrate structure related to type I chain (Nilsson et al., 1992) . It is related, although not identicaL to the antigenic epitopes of tumour markers CA 19-9 and CA 50.
In serum, the CA 242 epitope has been shown to be coexpressed with CA 50 and with sialylated Lewis, i.e. CA 19-9, on the same macromolecular complex (Johansson et al., 1991a, b) . This has made it possible to set up a solid-phase immunoassay, in which antibodie aginst sialylated Lewise and the C 242 antibody are used as 'catcher' and 'detector' antibodies respectively (Nilsson et al., 1988) . This assay has been shown to have a higher tumour specificity than the CA 50 test, which uses the C 50 antibody as both 'catcher' and 'detector' antibody (Johansson et al., 1991b measured by a dissociation-enhanced lanthanide fluoroimmunoassay (DELFHA) (Wallac Oy, Turku, Finland) as previously described (Nilsson et al., 1988 (Nilsson et al., , 1992 Kuusela et al., 1991) . An upper limit of normal of 20 U ml-', corresponding to the 99.4 percentile of healthy blood donors, has been recommended for the assay (Nilsson et al., 1988 (Metz, 1978) .
Results

CA 242 in pancreatic cancer
The serum level of CA 242 was higher than 20 U ml1 in 133 out of 179 patients with pancreatic cancer (74%) (Figure 1 , Table I (P= 0.24) . The CA 242 level in patients with pancreatic cancer was significantly higher than in patients with benign diseases (P=0.0001). This was also true when comparing different stages of pancreatic cancer with benign diseases (P = 0.0001).
CA 242 in benign diseases
The serum concentration of CA 242 was increased above the cut-off level of 20 U ml-' in 10 out of 112 patients (9%) with benign diseases of the pancreas, biliary tract and liver ( Figure  1 , Table I ). The median value was 6 U ml-', the mean value IOU ml-l and the highest value 111 U ml-'. Five out of 43 patients with benign biliary diseases (15%) had an increased serum concentration (median 6Uml-1, mean 12UmlV', range 0-11 U ml-'). All five patients had common bile duct stones with cholestasis. Of 42 patients with beign pancreatic diseases, elevated CA 242 levels were seen in three patients with chronic pancreatitis, but in none with acute pancreatitis (7%; median 6 U ml-', mean 10 U ml[', range 0-46 U ml-'). Of 27 patients with benign liver diseases, two patients with acute viral hepatitis had a slightly elevated CA 242 level (7%; median 4 U mlV ", mean 8 U ml'-, range 0-40 U ml ').
CA 19-9 in pancreatic cancer The serum CA 19-9 concentration was higher than 37 U ml-' in 148 out of 179 patients with pancreatic cancer (82.7%) ( Figure 1 , Table I (85%). The CA 19-9 level was significntly higher in stage II-III (P = 0.007) and in stage IV patients (P = 0.001) than in patients with stage I disease. The difference between stage H-HI and stage IV patients was non-significnt (P = 0.33).
The CA 19-9 lvel in all stages of pancreatic cancer was significntly higher than in patients with benign diseases (P = 0.0001).
CA 19-9 in benign diseases The serum concentration of CA 19-9 was increased above the cut-off level of 37Uml-' in 21 out of 112 patients with benig diseases of the pancreas, biliary tract and liver (19%; median 12 U ml-', mean 41 U ml-', range 0-1,400 U ml[') ( Figure 1 , Table I ). The CA 19-9 level was elevated in 12 out of 43 patients with benign biliary dis (28%; median 16 U ml-', mean 77 U ml-l, range 0-1,400 U ml-'). Nime of these patents had common bile duct stones with various degree of extrahepatic cholestasis, one patient had acute cholcystitis and two patients had gall bladder stones without chokcystitis. In benign pancreatic diseases CA 19-9 was elevated in three patients with chronic and two patients with acute pancreatitis (12%; median 10 U ml-', mean 20 U ml-', range 0-185 U ml-'). Four patients with benign liver disease (15%) had an elevated CA 19-9 serum level: two with viral hepatitis, one with cirrhosis, and one with acute alcoholic hepatitis.
Comparison of CA 242 and CA There was a high correlation between the CA 242 and CA 19-9 levels in serm (r2 = 0.732). The sensitivity of the CA 19-9 test for pancreatic cancer was higher than that of the CA 242 test in all stage groups, but the specificity was ckarly lower. When comparing the two markers by ROC curve analysis, the curves were nearly identical (Figure 2 ). At the 90% specificity leveL the sensitivity of CA 242 was 75% and that of CA 19-9 78%. The corrsponding cut-off levels were 19.5 U ml-' and 60 U ml-' r vely. At the 95% specificity leveL the sensitivities for CA 242 and CA 19-9 were 70% and 72%, respectively, and the cut-off values were 27 U ml-' and II Uml-' respectvely (Table I) . Using the recomnd cut-off values, two patients with pancreatic cancer had an elevated CA 242 level but a normal CA 19-9 level, while the opposite was true in 17 patients. If elevation of either CA 242 or CA 19-9 was considered a positive result, the overall sensitivity of the combination of 0.2-the markers was 84%. If both markers were required to be elevrated for a positive test result, the overall senstivity was 73%. The correponding specificities were 80% and 93% resectively.
Eight out of ten patients with benign diseases with elevated CA 242 level also had an ekevated CA 19-9 klvel. The highest serum levels of CA 19-9 were 1,400, 410 and 365 U ml-', and the corresponding CA 242 levels 58, 3 and 26 U ml-' respectively. The highet CA 242 levels were 111, 58 and 46 U ml-' and the corresponding CA 19-9 levels 126, 1,400 and 46Uml-'. The assay parameters for the CA 242 and CA 19-9 assays, and for the combinations of the tests, are summarised in Table II Using linear regression there was no correlation between the serum levels of tumour markers CA 242/CA 19-9 and serum bilirubin (r2=0.041/0.11) and alkalin phosphatase (r2 = 0.045/0.07).
During the 10 years that CA 19-9 has been available for clinical use (Del Villano et al., 1983) , it has gained a position as reference marker for pancreatic cancer, with which new markers are compared. Only some years after the presentation of CA 19-9, another tumour marker CA 50, recognising the same antigenic determinant, the sialylated Lewis antigen, was described (Lindholm et al., 1983) . In serum, both markers are associated with a high molkcular weight carbohydrate-rich mucin fraction (Lindholm et al., 1983; Magnani et al., 1983 ). Johansson et al. (1991a have demonstrated coexpression of CA 50 and sialylated Lewis, i.e. CA 19-9, on the same macromolcular complex, which they call CanAg. This macromolecule also expresses other antigens, including CA 242, a carbohydrate different from CA 19-9 and CA 50 (Nilsson et al., 1992) .
CA 242 is defined by monoclonal antibody C 242, obtained by the same immunisation procedure as the C 50 antibody . Different combinations of antibodies were studied in order to achieve optimal sensitivity and specificity for the macromolecule expressing these antigens (Johansson et al., 1991b ). An assay using an antibody against sialylated Lewis as catcher and the C 242 antibody as detector antibody showed better specificity for cancer than the CA 50 assay, which uses C 50 as both catcher and detector antibody. This assay has been introduced as the CA 242 marker test.
Preliminary results on the serum expression of CA 242 in pancreatic cancer were described in 1991 by Kuusela et al. Later other small series including 24-68 patients were reported (Nilsson et al., 1992; Pasanen et al., 1992; Banfi et al., 1993; R6thlin et al., 1993) . The results were promising and CA 242 has shown sensitivities and specficities similar to those of CA 19-9 and CA 50. For this study we colklcte a large series of 179 patients with pancreatic cancer, enabling Our study confirms previous obsations that the assay parameters of CA 242 are similar to those of CA 19-9 in the primary diagnosis of pancreatic cancer (Kuusela et al., 1991; Banfi et al., 1993; R6thlin et al., 1993) . The highest serum levels of CA 242 and CA 19-9 were found in patients with unresectable dies, which can be diagnosed by other clinical, radiological and laboratory investigations rather easily. In stage I disease, in which surgical treatment with curative intent is possible, more than half of the patients had ekevated CA 242 and CA 19-9 levels at the 90% seificity level (58% and 65% respectively). If five patients with resectable stage H-HI tumours were included, 60% of patients with resectable disease had an elevated CA 242 leveL and 67% an elevated CA 19-9 klvel.
There was a high correlation between the serum levels of CA 242 and CA 19-9. Using ROC curve analysis the results were nearly identical. Usually both markers were elevated in the same patients, and in most patients with either marker elevated and the other normal the difference in serum concentration was small. However, a small number of patients had a high CA 242 serm concentration but only slightly ekevated CA 19-9 or vie versa. These patients show that, in spite of the similarity of the markers, there are in some patients ckar differences in the expression of the antigens.
The reason for this is still not known.
When comparing the serm CA 242 klvel with the histological differentiation grade, stage IV patients with well-to moderately differentiated carcinomas had significntly higher CA 242 levels than patients with poorly differentiated carcinomas. This is in concordance with immunohistochemical findings showing ckarly stronger expression of CA 242 in well-to moderately differentiated tumours than in poorly differentiated or anaplastic carcinomas (Haglund et al., 1989 ). In stage I and H-HI patiets, poorly differentiated tumours semed to be associated with slightly higher CA 242 levels than well-to moderately differentiated tumours. However, the number of patients with poorly differentiated tumours in these stage groups was too small for definite conclusions to be drawn.
Because of the high correlation between the test results there was no advantage in combining CA 242 with CA 19-9 or CA 50. No correlation was sn between CA 242 and CEA. A combination of CA 242 and CEA increased the sensitivity by 7% at the 81% specificity klwl. Combination of CA 19-9 and CEA increased the sensitivity by 4% com-
F pared with CA 19-9 alone. However, the clnical utility of combining the tests is limited by the fact that the majority of patients with elevated CEA and normal CA 242 or CA 19-9 had disseminated disease.
The highest fiequency of false-positive CA 19-9 levels has been described in patients with extrahepatic jaundice (Jalanko et al., 1984; Haglund et al., 1986; Steinberg et al., 1986) , and this was confirmed in our study. In this patent group there was a difference between CA 19-9 and CA 242 in favour of CA 242. Although elevated CA 242 levels were found in some patints with common bile duct stones, the frequency of elevated levels was lower, and the increase in the serum concentration smaller than that of CA 19-9. When analysing all patients with benign di , sigfntly higher CA 19-9 levels were seen in jaundiced compared with non-jaundiced patients, whereas no signiant difference was seen for CA 242. The highest CA 19-9 serum concentrations have been reported in patients with cholangitis (Albert et al., 1988) . In the present study, one patient with a CA 19-9 value of 1,400 U ml ' had cholangitis. The corresponding CA 242 serum level was only 58 U ml-'. A larger series of patients with cholangitis should be colected to further evaluate the potential advantage of CA 242 over CA 19-9.
At the time of diagnosis, most patients with pancreatic cancer show extrahepatic cholstasis with elevated serum levels of bilirubin and alkaline phosphatase. It seems obvious that cholstasis contributes to eklvated marker levels in these patients. In stage H-IV cancer patients, the mean values of CA 19-9 and CA 242 appeared higher in jaundiced than in non-jaundiced patients, although the differences were not significnt. The P-vahles were lower for CA 19-9 than for CA 242, supporting the findings seen in benign diseases. In clinical practice, biliary decompresson has been found to reduce the CA 242 and CA 19-9 levels to a variable degree (C. Haglund et al., unpublished data). In spite of the higher frequency of elevated marker levels in cancer patients with cholstasis, there was no clear-cut correlation between the serum levels of these two tumour markers in malignant or benign diseases and the serum levels of bilirubin or alkaline phosphatase. This may be explaied by the fact that a minority of tumours do not express CA 242 or CA 19-9 (Haglund et al., 1989) , and these patients have a normal serum lvel even though they might be jaundied. On the other hand, some patients have high tumour production and strong serum expression of these antigens without obstruction of the common bile duct.
Preperatively, chronic pancreatitis can sometimes be very difficult to differentiate from pancreatic cancer. In these patients tumour markers might be helpful. Only three out of 20 patients with chronic pancreatitis had an elvated CA 242 level, but none of the patients with acute pancreatitis did. The highest value found in patients with chronic pancreatitis was 46 U ml-'. Hence Benign liver disease is frequently associated with elevated CA 19-9, CA 50 and CEA kevels (Jalanko et al., 1984; Chan et al., 1985; Steinberg et al., 1986) . In this study 4 of 27 patients had a slightly eklvated CA 19-9 level, but only two patients with acute viral hepatitis had an elevated CA 242 level. Our material included only a few patients with chronic liver diseas, and further studies are needed to evaluate the possible influence of chronic liver failure on the CA 242 level.
In conclusion, CA 19-9 has in many studies and in clnical practice been shown to be a useful complement to other diagnostic methods in symptomatic patients with pancreatic cancer. An elevated tumour marker level may kad to an intensifed search for pancreatic cancer. In this study we report the results on a novel tumour marker, CA 242, which are similar to those of CA 19-9 in the primary diagnosis of pancreatic cancer. In clinical work, the higher specificity when using the recommended cut-off levels of the tests is a clear advantage of CA 242 compared with CA 19-9. Studies comparing CA 242 and CA 19-9 in follow-up and as prognostic markers are ongoing, and will help to decide whether CA 242 might replace CA 19-9 as the standard marker for pancreatic cancer. CA 242 also seems to be very promising in the diagnosis of colorectal cancer (Kuusela et al., 1991; Nilsson et al., 1992) . If CA 242 becomes a routine marker for colorectal cancer, it would seem to be convenient to use the same marker in patients with pancreatic cancer.
